New opportunities of systemic therapy of CD30-positive primary cutaneous T-cell lymphomas

Cover Page
  • Authors: Poddubnaya I.V.1, Ptushkin V.V.2,3, Belousova I.E.4,5, Gorenkova L.G.6, Kaplanov K.D.7, Karamova A.E.8, Kovrigina A.M.9,10, Kolomeitsev O.A.11, Konstantinova T.S.12, Kokhan M.M.13, Pospelova T.I.14
  • Affiliations:
    1. Russian Medical Academy of Continuous Professional Education
    2. City Clinical Hospital named after S.P. Botkin, Moscow Department of Health
    3. Moscow City Hematology Center
    4. S.M. Kirov Military Medical Academy
    5. Saint Petersburg Medical and Social Institute
    6. National Research Center for Hematology, Department of Intensive High-Dose Chemotherapy with Round-the-Clock and Day Hospital (IVHT with CS and DS)
    7. Volgograd Regional Clinical Oncology Center
    8. Federal State Budgetary Institution “State Scientific Center of Dermatovenerology and Cosmetology” of the Ministry of Health of Russia
    9. National Medical Research Center of Hematology, Ministry of Health of Russia
    10. Institute for Advanced Studies
    11. FSBI “National Medical Research Center of Oncology named after N.N. Blokhina» Ministry of Health of Russia
    12. Sverdlovsk Regional Clinical Hospital No. 1
    13. Ural Research Institute of Dermatovenerology and Immunopathology
    14. Novosibirsk State Medical University
  • Issue: Vol 22, No 2 (2020)
  • Pages: 79-81
  • Section: Conference Proceedings
  • URL: https://modernonco.orscience.ru/1815-1434/article/view/34929
  • DOI: https://doi.org/10.26442/18151434.2020.2.200205
  • Cite item

Abstract


Relevance. Cutaneous T-cell lymphomas (CTCL) are not common diseases which are associated with a decrease in quality of life. Currently available systemic therapy rarely provides a stable and long-termed response. In Russia, current CTCL therapy is a big issue due to the limited access to modern targeted therapy, an absence of a National CTCL registry, and the difficulties in morphological diagnosis of these rare diseases. Since June 17, 2019, a new indication of brentuximab vedotin as a new treatment option for patients with CD30+ CTCL after at least one line of previous systemic therapy was registered. Brentuximab vedotin is a conjugate of a CD30 directed monoclonal antibody and an antitumor agent. Brentuximab vedotin is a CD30-directed monoclonal antibody conjugated to an antitumor agent.

Aim. To identify the unresolved issues of current clinical practice and to adapt available approaches to the treatment and diagnosis of CD30 + CTCL given new therapeutic opportunities.

Results. The available approaches to the systemic CTCL therapy in Russia routine clinical practice have been discussed, the unresolved issues of therapy and diagnosis have been identified, the routing of patients with CD30 + CTCL in Russia has been discussed, the importance of CD30 testing has been established, the profiles of patients with CTCL for treatment with brentuximab vedotin have been determined.


Full Text

Restricted Access

About the authors

Irina V. Poddubnaya

Russian Medical Academy of Continuous Professional Education

Author for correspondence.
Email: ivprectorat@inbox.ru
ORCID iD: 0000-0002-0995-1801

Russian Federation, Moscow

D. Sci. (Med.), Prof., Acad. RAS

Vadim V. Ptushkin

City Clinical Hospital named after S.P. Botkin, Moscow Department of Health; Moscow City Hematology Center

Email: or@hpmp.ru

Russian Federation, Moscow

Doctor of Medical Sciences, Professor

Irena E. Belousova

S.M. Kirov Military Medical Academy; Saint Petersburg Medical and Social Institute

Email: irena.belousova@mail.ru
Saint Petersburg

D. Sci. (Med.), Prof.

L. G. Gorenkova

National Research Center for Hematology, Department of Intensive High-Dose Chemotherapy with Round-the-Clock and Day Hospital (IVHT with CS and DS)

Email: or@hpmp.ru
ORCID iD: 0000-0002-3967-9183

Russian Federation, Moscow

врач-гематолог отд. ИВХТ с КС и ДС 

Kamil D. Kaplanov

Volgograd Regional Clinical Oncology Center

Email: or@hpmp.ru

Russian Federation, Volgograd

Candidate of Medical Sciences

A. E. Karamova

Federal State Budgetary Institution “State Scientific Center of Dermatovenerology and Cosmetology” of the Ministry of Health of Russia

Email: or@hpmp.ru

Russian Federation, Moscow

Cand. med. sciences, dermatologist, head. Dep. dermatology

Alla M. Kovrigina

National Medical Research Center of Hematology, Ministry of Health of Russia; Institute for Advanced Studies

Email: or@hpmp.ru

Russian Federation, Moscow

Dr. med. sciences, pathologist, prof. cafe pathological anatomy, cytology and molecular pathology; Head pathoanatomical department; Member of the Presidium of the Russian Society of Pathologists, Member of the Board of the Russian Professional Society of Oncohematologists, Member of the National Hematology Society

O. A. Kolomeitsev

FSBI “National Medical Research Center of Oncology named after N.N. Blokhina» Ministry of Health of Russia

Email: or@hpmp.ru

Russian Federation, Moscow

Oncologist, Scientific Advisory Department, Clinical Oncology Research Institute N.N. Trapeznikova

T. S. Konstantinova

Sverdlovsk Regional Clinical Hospital No. 1

Email: or@hpmp.ru

Russian Federation, Yekaterinburg

Cand. med. sciences, head. Department of Hematology, hematologist of the highest category, chapters. Freelance hematologist of the Ural Federal District and the Ministry of Health of the Sverdlovsk Region

Muza M. Kokhan

Ural Research Institute of Dermatovenerology and Immunopathology

Email: or@hpmp.ru

Russian Federation, Yekaterinburg

Dr. med. sciences, prof., head. Scientific Clinical Dep. Dermatology, Honored Doctor of the Russian Federation

Tatyana I. Pospelova

Novosibirsk State Medical University

Email: or@hpmp.ru

Russian Federation, Novosibirsk

Dr. med. sciences, professor, hematologist, head. cafe therapy, hematology and transfusiology, hands. City Hematology Center

References

  1. Инструкция по медицинскому применению лекарственного препарата Адцетрис® (РУ № ЛП-003476 от 26.02.2016), изменение №4 от 17.06.2019. [Instruktsiia po meditsinskomu primeneniiu lekarstvennogo preparata Adtsetris® (RU № LP-003476 ot 26.02.2016), izmenenie №4 ot 17.06.2019 (in Russian).]
  2. Prince HM, Kim YH, Horwitzet SM et al. Brentuximab vedotin or physician’s choice in CD30-positive cutaneous T-cell lymphoma (ALCANZA): an international, open-label, randomised, phase 3, multicentre trial. Lancet 2017; 390: 555–66.
  3. Scarisbrick J, Horwitz S, Dummer R et al. Final ALCANZA results: brentuximab vedotin versus physician’s choice in previously treated CD30-positive cutaneous T-cell lymphoma (Mycosis fungoides or primary cutaneous anaplastic large cell lymphoma. Abstract V-05. 4 WCCL, 12-14.
  4. Клинические рекомендации МЗ по грибовидному микозу. http://cr.rosminzdrav.ru/#!/recomend/859 [Klinicheskie rekomendatsii MZ po gribovidnomu mikozu. http://cr.rosminzdrav.ru/#!/recomend/859 (in Russian).]
  5. Клинические рекомендации МЗ по синдрому Сезари. http://cr.rosminzdrav.ru/#!/recomend/991 [Klinicheskie rekomendatsii MZ po sindromu Sezari. http://cr.rosminzdrav.ru/#!/recomend/991 (in Russian).]
  6. Duvic M, Tetzlaff MT, Gangar P. Results of a Phase II Trial of Brentuximab Vedotin for CD30+ Cutaneous T-Cell Lymphoma and Lymphomatoid Papulosis. J Clin Oncol 2015; 33 (32): 3759–65. doi: 10.1200/JCO.2014.60.3787
  7. NCCN Clinical Practice Guidelines. Primary cutaneous lymphomas V.2-2020 https://www.nccn.org/professionals/physician_gls/pdf/primary_cutaneous.pdf
  8. Willemze R, Hodak E., Zinzani PL et al. Primary Cutaneous Lymphomas: ESMO Clinical Practice Guidelines. Ann Oncol 2018; 29 (Suppl. 4): iv30–iv40.

Supplementary files

Supplementary Files Action
1.
Progression-free survival, centralized assessment (observation period 36.8 months)

Download (127KB) Indexing metadata

Statistics

Views

Abstract - 19

PDF (Russian) - 5

Cited-By


PlumX

Dimensions

Refbacks

  • There are currently no refbacks.


Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies